Germline Mismatch Repair Variant Detection and Surveillance Outcomes in Patients with Lynch Syndrome: A Review
DOI:
https://doi.org/10.5281/zenodo.22207640Keywords:
Lynch Syndrome, Mismatch Repair, Colonoscopic Surveillance, Gene-Specific Risk, Colorectal CancerAbstract
Lynch syndrome is the commonest inherited cause of colorectal cancer, and carriers are enrolled in colonoscopic surveillance on the assumption that removing adenomas prevents cancer. Prospective data show cancers continuing to occur at high rates despite that surveillance, and no advantage from shortening the interval. Objectives: To review the published evidence on germline mismatch repair variant detection and surveillance outcomes in Lynch syndrome: how carriers are identified, what cancer risk each gene confers, what colonoscopic surveillance achieves, and why shorter intervals have not delivered what was expected. Material and Methods: Narrative review of prospective cohort reports, registry analyses, comparative surveillance studies and society guidelines indexed
in PubMed and the major gastroenterology and genetics journals. Studies were eligible if they reported gene-specific cancer risk in variant carriers, the yield or performance of detection strategies, or outcomes of colonoscopic surveillance. No new patient data were generated; every estimate quoted is one published by the original investigators. Results: Among 8,500 carriers under colonoscopic surveillance, cumulative colon cancer risk by age 65 was 48.4, 41.5, 12.7 and 9.5 per cent in men and 36.3, 29.8, 10.1 and 2.8 per cent in women for path_MLH1, path_MSH2, path_MSH6 and path_PMS2 respectively. Rectal cancer followed a different ordering, highest in path_MSH2 at 12.6 per cent in men. In 6,350 carriers, no significantly increased cancer risk was demonstrated for path_PMS2, and
path_MSH6 behaved as a sex-limited trait with high endometrial but only modestly raised colorectal risk. Among 218 cancers diagnosed during surveillance, the proportion presenting at stage III or IV did not differ by time since the previous colonoscopy, at 16.7, 19.4, 9.9 and 15.1 per cent across intervals of under 1.5, 1.5 to 2.5, 2.5 to 3.5 and over 3.5 years (p = 0.34). Conclusion: Gene-specific risk differs enough that a single surveillance protocol for all carriers is not defensible, and current guidelines have moved
accordingly. The absence of any stage or incidence benefit from shorter intervals suggests that colorectal cancer in this syndrome does not always arise through a slow adenoma sequence, which is the premise surveillance was built on. Abbreviations: LS – Lynch Syndrome, MMR – Mismatch Repair, path_MMR – Pathogenic Mismatch Repair Variant, CRC – Colorectal Cancer, MSI – Microsatellite Instability, dMMR – Deficient Mismatch Repair, IHC – Immunohistochemistry, EPCAM – Epithelial Cell Adhesion Molecule, PLSD –
Prospective Lynch Syndrome Database, EHTG – European Hereditary Tumour Group, ESCP – European Society of Coloproctology, AJCC – American Joint Committee on Cancer.
References
Møller P, Haupt S, Ahadova A, Kloor M, Sampson JR, Sunde L, et al. "Incidences of colorectal adenomas and cancers under colonoscopy surveillance suggest an accelerated Big Bang pathway to CRC in three of the four Lynch syndromes". Hered Cancer Clin Pract 22(2024):6.
Seppälä TT, Latchford A, Negoi I, Sampaio Soares A, Jimenez-Rodriguez R, Sanchez-Guillen L, et al. "European guidelines from the EHTG and ESCP for Lynch syndrome: an updated third edition of the Mallorca guidelines based on gene and gender". Br J Surg 108(2021):484-498.
Vasen HFA. "Progress report: new insights into the prevention of CRC by colonoscopic surveillance in Lynch syndrome". Fam Cancer 21(2022):49-56.
Vasen HF, Tomlinson I, Castells A. "Clinical management of hereditary colorectal cancer syndromes". Nat Rev Gastroenterol Hepatol 12(2015):88-97.
Mecklin JP. "Frequency of hereditary colorectal carcinoma". Gastroenterology 93(1987):1021-1025.
Jass JR, Stewart SM. "Evolution of hereditary non-polyposis colorectal cancer". Gut 33(1992):783-786.
Lynch HT, de la Chapelle A. "Hereditary colorectal cancer". N Engl J Med 348(2003):919-932.
Pearlman R, Frankel WL, Swanson B, Zhao W, Yilmaz A, Miller K, et al. "Prevalence and spectrum of germline cancer susceptibility gene mutations among patients with early-onset colorectal cancer". JAMA Oncol 3(2017):464-471.
Hill MJ, Morson BC, Bussey HJ. "Aetiology of adenoma-carcinoma sequence in large bowel". Lancet 1(1978):245-247.
Järvinen HJ, Aarnio M, Mustonen H, Aktan-Collan K, Aaltonen LA, Peltomäki P, et al. "Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer". Gastroenterology 118(2000):829-834.
Giardiello FM, Allen JI, Axilbund JE, Boland CR, Burke CA, Burt RW, et al. "Guidelines on genetic evaluation and management of Lynch syndrome: a consensus statement by the US Multi-Society Task Force on colorectal cancer". Gastroenterology 147(2014):502-526.
Seppälä TT, Dominguez-Valentin M, Møller P, et al. "Metachronous colorectal cancer risks after extended or segmental resection in MLH1, MSH2 and MSH6 Lynch syndrome: multicentre study from the Prospective Lynch Syndrome Database". Br J Surg 112(2025):znaf061.
Dominguez-Valentin M, Sampson JR, Seppälä TT, ten Broeke SW, Plazzer JP, Nakken S, et al. "Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrome Database". Genet Med 22(2020):15-25.
ten Broeke SW, van der Klift HM, Tops CMJ, Aretz S, Bernstein I, Buchanan DD, et al. "Cancer risks for PMS2-associated Lynch syndrome". J Clin Oncol 36(2018):2961-2968.
Seppälä T, Pylvänäinen K, Evans DG, Järvinen H, Renkonen-Sinisalo L, Bernstein I, et al. "Colorectal cancer incidence in path_MLH1 carriers subjected to different follow-up protocols: a Prospective Lynch Syndrome Database report". Hered Cancer Clin Pract 15(2017):18.
Engel C, Vasen HF, Seppälä T, Aretz S, Bigirwamungu-Bargeman M, de Boer SY, et al. "No difference in colorectal cancer incidence or stage at detection by colonoscopy among 3 countries with different Lynch syndrome surveillance policies". Gastroenterology 155(2018):1400-1409.
Seppälä TT, Ahadova A, Dominguez-Valentin M, Macrae F, Evans DG, Therkildsen C, et al. "Lack of association between screening interval and cancer stage in Lynch syndrome may be accounted for by over-diagnosis; a prospective Lynch syndrome database report". Hered Cancer Clin Pract 17(2019):8.
Gøtzsche PC, Jørgensen KJ. "Screening for breast cancer with mammography". Cochrane Database Syst Rev (2013):CD001877.
Møller P, Seppälä T, Bernstein I, Holinski-Feder E, Sala P, Evans DG, et al. "Cancer incidence and survival in Lynch syndrome patients receiving colonoscopic and gynaecological surveillance: first report from the Prospective Lynch Syndrome Database". Gut 66(2017):464-472.
Engel C, Ahadova A, Seppälä TT, Aretz S, Bigirwamungu-Bargeman M, Bläker H, et al. "Associations of pathogenic variants in MLH1, MSH2, and MSH6 with risk of colorectal adenomas and tumors and with somatic mutations in patients with Lynch syndrome". Gastroenterology 158(2020):1326-1333.
Haanstra JF, Vasen HFA, Sanduleanu S, van der Wouden EJ, Koornstra JJ, Kleibeuker JH, et al. "Quality colonoscopy and risk of interval cancer in Lynch syndrome". Int J Colorectal Dis 28(2013):1643-1649.
Rees CJ, Thomas Gibson S, Rutter MD, Baragwanath P, Pullan R, Feeney M, et al. "UK key performance indicators and quality assurance standards for colonoscopy". Gut 65(2016):1923-1929.
Goverde A, Eikenboom E, Viskil E, Bruno M, Dubbink HJ, Dinjens WNM, et al. "Yield of Lynch syndrome surveillance for patients with pathogenic variants in DNA mismatch repair genes". Clin Gastroenterol Hepatol 18(2020):1112-1120.
Boland CR, Goel A. "Microsatellite instability in colorectal cancer". Gastroenterology 138(2010):2073-2087.
Hampel H, Frankel WL, Martin E, Arnold M, Khanduja K, Kuebler P, et al. "Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer)". N Engl J Med 352(2005):1851-1860.
